Skip to content

IP License - FOXP3+ Helios+ Engineered Regulatory T cells

IP Licensing
Availability: Available On Demand

For informational purposes only. Please contact seller directly for more details.

Share This:

Children’s Mercy Kansas City, together with the University of Kansas, has developed a novel cell-based therapy to combat disordered inflammation. Using a novel method, CD4+ and CD8+ regulatory T cells have been engineered to over express both FOXP3 and Helios without suppression of either product. Efficacy of the eTregs has been shown in vitro and in a humanized model of graft versus host disease (GVHD). CD4+ and CD8+ cells can be separated if preferred. This innovation is applicable in the treatment of diseases in which it is desirable to reduce inflammatory immune response such as type 1 diabetes, multiple sclerosis, allograft/transplant rejection, inflammatory bowel disease, lupus, rheumatoid arthritis, and other chronic inflammatory diseases. If interested in licensing and/or research collaborations, contact Children’s Mercy Kansas City to have discussions. US Patent Issued, Second US and International patents pending.

Shipping Information

Digital delivery/downloads will typically be delivered within 2 business days.

Physical products typically take 5-8 business days. Please contact the seller directly with any questions about your order.

You will receive an order confirmation email from PedsMrkt followed by a shipping email when your order ships.


Please contact the seller directly for their return policy and to
handle returns. Customer will be responsible for return shipping fees.